Hologic cuts annual revenue forecast on weak demand for breast health products

Hologic

05/02/2025 22:54

Feb 5 (Reuters) - Hologic  HOLX.O  lowered its fiscal
2025 revenue forecast, citing weakness in sales of its breast
health products, sending the company's shares down 5% after the
bell on Wednesday.
    The company manufactures and supplies viral load tests,
molecular diagnostics assays, medical imaging systems and
surgical products focused on women's health.
    Ongoing saline shortage, caused by hurricane-related
disruptions at a key facility, could affect some of the
company's breast and surgical procedures in the second quarter.
    Hologic cut its annual sales forecast for fiscal 2025 to a
range of $4.05 billion to $4.10 billion, compared with its prior
forecast of $4.15 billion to $4.20 billion.
    Analysts were expecting annual sales of $4.16 billion.
    Hologic has also been facing delays in its shipment of
skeletal health products since late in the third quarter due to
a temporary halt as some products did not conform to certain
standards.
    The company said it resumed some shipments in December.
    Still, Hologic's diagnostics business, its largest by
revenue, reported sales of $470.6 million, compared with the
average analyst estimate of $461 million, according to data
compiled by LSEG.
    The company's total revenue rose marginally to $1.02 billion
in the first quarter, in line with estimates.
    Hologic's skeletal health business reported first-quarter
revenue of $15.8 million, down 37.8%.
    The company maintained its annual adjusted profit forecast
of $4.25 to $4.35 per share. Analysts were expecting a profit of
$4.26.

 (Reporting by Unnamalai L in Bengaluru; Editing by Alan Barona
and Shounak Dasgupta)
 ((Unnamalai.L@thomsonreuters.com))